Comparing Peptides by Safety Data and Monitoring Needs

Why monitoring differs between peptides

The peptides people use for recovery, fat loss or growth hormone effects don't share a safety profile, and they don't share a body of evidence either. Some have an FDA label that tells prescribers which blood tests to run. Others have never been given to a person in a published study. That gap decides what blood work can realistically show, so this page compares the main compounds on two questions: what human data exists, and which lab signals it points to.

A 2026 review in Frontiers in Endocrinology (Dominikowski and colleagues) sorted growth hormone axis peptides into evidence tiers, from tier A (randomized trials within an approved use) to tier D (no peer-reviewed human studies). It also mapped which hormone changes each class has produced in people. The comparison below leans on that review plus FDA labels and advisory committee reviews. For the general baseline panel, see our overview of baseline and on-cycle lab tests.

How much human safety data each peptide has

GHRH analogues: tesamorelin and CJC-1295

Tesamorelin is the only compound here with label-level monitoring rules, because it's a prescription medicine (Egrifta) approved to reduce abdominal fat in adults with HIV-associated lipodystrophy. Its 2025 label tells prescribers to check glucose before and during treatment and to monitor IGF-1.

The trial numbers explain why. After 26 weeks on tesamorelin, 47% of patients had IGF-1 more than 2 standard deviations above normal, with the rise showing as early as week 13. HbA1c reached 6.5% or higher, the diabetes threshold, in 5% of the tesamorelin group versus 1% on placebo. The label also describes fluid retention. These were supervised patients, not gray-market users.

CJC-1295 with DAC has far less behind it. In two small randomized studies in healthy adults (Teichman, 2006), one injection raised IGF-1 1.5- to 3-fold for 9-11 days, and with repeated doses IGF-1 stayed above baseline for up to 28 days. That long tail matters when reading results, since an IGF-1 test reflects several recent injections. FDA's 2024 review of the human studies found injection-site reactions in about 70% of participants after a single dose, plus flushing and a faster heart rate. A Phase 2 trial was stopped after a participant had a fatal heart attack 2 hours after an 11th weekly dose. The physician blamed underlying heart disease, and FDA could find only an anecdotal report online.

An earlier version of this page said the DAC form causes a constant "GH bleed" that is harder on insulin sensitivity. The human data don't show that. Ionescu and Frohman (2006) sampled GH every 20 minutes overnight in healthy men a week after one dose. Pulses kept their normal frequency and size, while trough GH rose 7.5-fold and IGF-1 rose 45%. Secretion stayed pulsatile, just on a higher floor. Our CJC-1295 profile covers both forms; the no-DAC version most users describe sits in the review's tier D.

GHRPs and ipamorelin: the cortisol and prolactin question

The ghrelin-mimicking GH secretagogues split into two groups on lab signals. GHRP-2 and GHRP-6 raise more than GH. In a 1999 study, 7 young adults given a single IV dose of GHRP-2 had significant rises in prolactin and cortisol along with GH. FDA's safety summary cites cortisol and blood glucose effects for GHRP-6, and reports of increased insulin needs with GHRP-2 (causality not established).

Ipamorelin was developed to avoid the cortisol and prolactin effects, and the 2026 review classes it as sparing on both. Its human record is thin, though. A Phase 2 trial in 117 hospitalized adults after abdominal surgery missed its primary endpoint, and the ipamorelin group had more low potassium and high blood sugar at discharge than placebo. Two people in the ipamorelin arms died after treatment ended; FDA's 2024 review said it was unclear whether the deaths were related.

The practical difference is interpretation. The review advises clinicians that a mildly high cortisol or prolactin in someone using GHRP-2 or GHRP-6 likely reflects the compound and should be retested after stopping, before anyone orders pituitary imaging. On ipamorelin alone, the same result would be less expected.

Timing matters too. In a 1998 study, 9 healthy young men received 100 mcg of GHRP-2 by daily subcutaneous injection for 5 days. Their GH response shrank by day 5, and IGF-1 didn't rise. So a flat IGF-1 on a GHRP doesn't by itself prove a vial was fake, a common forum assumption. Tolerance and on/off schedules are covered in our article on peptide cycling and blood work.

IGF-1 LR3: no human data and a different acute risk

IGF-1 LR3 isn't a secretagogue. It's an engineered form of IGF-1 that acts on the IGF-1 receptor directly. The 2026 review found no peer-reviewed human studies of any kind, not even a measured half-life.

Users consistently describe hypoglycemia as the main acute risk, which the review calls biologically plausible given IGF-1's insulin-like activity. Many say they keep a glucose meter on hand and eat carbohydrates around injections; that's community practice, not a tested protocol. A blood panel weeks later can't capture a low that happens shortly after an injection. We also found no published data on how LR3 registers on a standard IGF-1 test. The longer-term worry, that IGF-1 signaling drives cell growth, is theoretical, and no routine test tracks it.

AOD-9604: trials measured labs, but only for oral and IV use

AOD-9604 is a fragment of the growth hormone molecule, and it's one of the few compounds here where human trials ran broad safety labs. FDA's 2024 briefing summarizes six sponsor-funded randomized trials, oral or IV, that measured routine blood work, glucose tolerance and IGF-1. The authors, who worked for or consulted for the sponsor, reported no statistically significant changes. The largest, the 24-week OPTIONS study of 502 adults with obesity, missed its weight-loss endpoint.

In a 12-week oral trial, serious adverse events in the AOD-9604 groups included several cancers. Investigators judged them unrelated, but FDA said the information was too thin to tell. No human study has tested subcutaneous injection, the route users report, so "no lab changes in trials" applies to oral and IV doses only.

BPC-157 and TB-500: missing data, not proven safety

Earlier versions of this page called the safety record of these two clean, citing decades of animal work. That overstates the evidence. A 2025 systematic review of BPC-157 in orthopedic sports medicine included 36 studies, 35 of them preclinical, and found no clinical safety data. Animal studies showed no organ damage, but none looked at adverse events beyond 6 weeks. The closest thing to a human lab study is a 2025 pilot in which 2 adults received IV BPC-157 (10 mg, then 20 mg the next day) with no measurable change in organ or glucose markers. Two people over two days can't establish safety.

The claim that BPC-157 acts only locally doesn't hold up well either. In animal studies it stimulates VEGF and other pathways tied to angiogenesis, often after systemic dosing. Encouraging blood vessel growth raises a theoretical tumor question that hasn't been studied in people. Our BPC-157 profile has the full evidence picture.

TB-500 has even less. It's a short fragment of thymosin beta-4, not the full protein; an earlier version of this page had that backwards. As of October 2026, FDA's safety summary says it has found no human exposure data for the fragment, and trials of the full protein don't carry over. With no known drug effect to track, a lab panel here works as a general health check.

What a lab result can and can't tell you

Blood tests can only track signals that human studies have documented: IGF-1 and glucose for the GHRH analogues, plus cortisol and prolactin for GHRP-2 and GHRP-6. The 2026 review suggests fasting glucose or HbA1c is worth checking whatever the compound. Where no human data exist, a normal result rules out only what was tested.

Results also depend on what's in the vial. Gray-market products aren't made to drug standards, so an unchanged IGF-1 can reflect a weak product as easily as tolerance. An odd result can come from contamination or another drug used alongside. The review stresses that symptoms often stem from combinations, especially with anabolic steroids, rather than one peptide.

No study has tested a monitoring schedule for any research peptide. The only labeled monitoring guidance belongs to tesamorelin, written for patients under a prescriber's care. The review's red flags for urgent care include severe breathlessness with rapid fluid retention, markedly high blood sugar, and severe headaches with vision changes.

What we still don't know

• Long-term safety outside tesamorelin's approved use. The 2026 review reports no long-term safety data for nearly every peptide it covers. Our article on long-term effects looks at monitoring over years.
• Whether CJC-1295 with DAC affects glucose control over months of use.
• How IGF-1 LR3 behaves in people, including its half-life.
• Whether BPC-157 has effects a blood test would catch. A University of Arkansas trial of about 30 patients after rotator cuff surgery (NCT07803250), planned to start in January 2027, will collect blood biomarkers.